Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

Inclusion Criteria: * Participants aged ≥19 years with histologically OR cytologically confirmed locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) * Participants aged ≥12 years with solid tumors harboring Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions * Documented ROS1 or NTRK 1-3 gene fusion by validated local testing * Written informed consent Exclusion Criteria: * Treatment with repotrectinib for indications not approved in Korea * Treatment with repotrectinib at dosages not approved in Korea * Contraindication to repotrectinib according to MFDS prescribing information